 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C12H12N2O2 |
| Molar mass | 216.240 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
Cyclazodone is a centrally actingstimulant drug developed byAmerican Cyanamid Company in the 1960s.[1] The drug is related to other drugs such aspemoline andthozalinone. It displayed a favorable therapeutic index and margin of safety in comparison to most other pemoline derivatives.[2] The patents concluded that cyclazodone possessed properties efficacious in reducing fatigue and as a potential anorectic.[3] Structural congeners of pemoline have been described as "excitants with unique properties distinguishing them from the sympathomimetic amines" whilst displaying less stimulatory activity and toxicity compared to amphetamine.[4]
It is included under theWorld Anti-Doping Agency prohibited list.[5]
Cyclazodone has not been evaluated by the United States Food and Drug Administration for use in humans as a nootropic, anorectic, or stimulant and thus safety information is lacking. However, in studies relating to the therapeutic uses of cyclazodone, it was noted that it exhibited less cardiotoxic effects thandextroamphetamine in studies on mice.[2]
α-Chlorophenylacetyl chloride (1) and N-cyclopropylurea (2) react to give thediketone (3).Ring closure withsodium ethoxide in ethanol completes the synthesis.[2][6]
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byadding missing information. |
